Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, the correlation of NEDD4L and HIF-1α levels may act as a prognostic marker of GC.
|
31673244 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Krüppel-like factor 5 (KLF5) and hypoxia-inducible factor-1α (HIF-1α) are important transcription factors in the development of gastric cancer.
|
30851060 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, HDAC1 promotes glycolysis in GC and affects HIF-1α activity in tumor progression and metastasis.
|
30500418 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical staining suggested that the expression levels of LOX and HIF1α increased in tumor tissues from patients with GC.
|
31057297 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Stable HE4 knockdown and HIF1α overexpression were introduced into GC cell lines to study the role of HE4 in the resistance of GC to radiation therapy.
|
30705965 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MicroRNA-30c expression was suppressed by hypoxia-inducible factor-1α activation and related to decreased mTOR activity as well as glycolysis in human GC TAMs.
|
31222863 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, it may be concluded that HIF-1α, GLUT1 and LDH-5 are potential target genes involved in the endogenous tumor response to hypoxia and the inhibition of tumor energy metabolism, highlighting a novel therapeutic target for GC.
|
31423208 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacologic manipulation of HIF-1α may provide a novel therapeutic approach to gastric cancer.
|
30782242 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HER2-HIF-1α-LDHA axis may serve as the basis for new methods and strategies for the treatment of GC.
|
30093943 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To this end, 428 GC tissue samples were used to analyze the expression of HIF-1α and P4HB <i>via</i> immunohistochemical staining.
|
29904245 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified PLOD2 regulated by HIF-1 as a potential regulator of peritoneal dissemination of GC.
|
29603227 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
PA treatment induces the expression of pro-apoptotic factor Bax by inhibiting hypoxia/HIF1[Formula: see text], supporting the therapeutic potential of PA in radiation therapy against GC.
|
29737213 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum HIF-1α showed promising diagnostic and prognostic values for gastric cancer.
|
29899167 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, we observed that GX1 could inhibit the GTP-binding activity of TGM2 by reducing its intracellular distribution and downregulating its downstream molecular targets (nuclear factor-kappa B, NF-κB; hypoxia-inducible factor 1-α, HIF1α) in GC vascular endothelial cells.
|
29785022 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Material and methods:</b> hypoixa by expression of hypoxia-inducible factor-1 alpha (HIF-1α), polarized functional status of infiltrated TAMs by immunohistochemical staining of CD68 and CD163, and the expression of E-cadherin as EMT property had been evaluated in 236 patients consecutive with histologically confirmed GC.
|
28819379 |
2017 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings implicated that RBMS3 and nuclear HIF1A could act as prognostic biomarkers and therapeutic targets for GC.
|
27902480 |
2017 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
PHD3 affects gastric cancer progression by negatively regulating HIF1A.
|
28901473 |
2017 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the potential mechanisms of HIF-1α and miR-421 in gastric cancer have not been well elucidated.
|
27016414 |
2016 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
We showed that aberrant expression of miR-20b, miR27a and miR-181a was associated with chemotherapeutic response in GC through HIF1A, MDR1 and HIPK2 genes modulation, suggesting a possible novel therapeutic strategy.
|
26793992 |
2016 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In cell culture, FOXO1 silencing enhanced hypoxia inducible factor-1α (HIF-1α) expression and GC cell growth under hypoxic conditions, but not under normoxic conditions.
|
25761483 |
2016 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
HIF-1 is a driver of gastric cancer and considered to be an attractive target for therapy.
|
26760764 |
2016 |
Malignant neoplasm of stomach
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In the present study, real time-PCR and Western blot were performed to detect the expression of HIF-1α in GC tissues and cell lines.
|
26292288 |
2015 |
Malignant neoplasm of stomach
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Apoptotic Effect of HIF-1α Inhibition Combined with Glucose plus Insulin Treatment on Gastric Cancer under Hypoxic Conditions.
|
26339797 |
2015 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The data showed that expression levels of RAP1B and HIF-1α proteins were high in the GC tissue specimens, and RAP1B expression was significantly associated with tumor-node-metastasis (TNM) stage and tumor size, while HIF-1α expression was significantly associated with TNM stage, Borrmann type and tumor differentiation.
|
26329876 |
2015 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Quantitative real-time PCR was used to analyze the expression of miR-107 and HIF-1α in 36 pairs of fresh gastric cancer and matched adjacent normal tissue specimens and the serum of these patients compared to age matched controls.
|
26406411 |
2015 |